Version Française
NEWS RSS
25/04/2017
“The Benelux Pharmacovigilance Day 2016”.

Come and join us at “The Benelux Pharmacovigilance Day 2016” on October 11, 2016, in Amsterdam....

25/04/2017
"Risk minimization in data anonymization process"

Come and join us in Barcelona for the 2016 PhUse annual conference. ...

25/04/2017
KeyrusBiopharma is going to be present on the “BCF Career Event Belgium”.

KeyrusBiopharma is going to be present on the “BCF Career Event Belgium”....

25/04/2017
DII 3rd annual conference on

DII 3rd annual conference on "Health data revolution"...

All news
About Us

Keyrus Biopharma Introduction

Founded in 1998, Keyrus Biopharma, a European CRO (Contract Research Organisation) is a major player in clinical research, with 240 employees located in France (Paris, Evry, Nantes), Belgium(Waterloo, Mont St Guibert), Lebanon (Beirut) and Tunisia (Tunis).

Capitalising on a solid experience in clinical research and a lasting relationship with its clients, Keyrus Biopharma focuses its development strategy on innovation and creativity to offer high standard solutions to its clients.

From pharmaceutical industries to medical device, nutrition, cosmetics and biotechnology

Based on its expertise gained over more than 15 years in clinical research, Keyrus Biopharma has been able to meet the needs of clients in medical device, nutrition and cosmetic domains and to develop partnerships with the biotechnology industry.

This diversity of experience and the know-how of Keyrus Biopharma result from a close collaboration based on innovation and a customer focused orientation. It is enhanced by the dedication of team members to Keyrus Biopharma’s strategy based on expertise and skills development.

As a result, Keyrus Biopharma offers a wide range of solutions and services using the proficiency of its team and the command of the latest technologies (Oracle® Clinical, e-CRF, SAP BusinessObjects®, SAS®, etc)

As a specialist in your area, Keyrus Biopharma efficiently assists you in your projects:

  • whatever their specificity
  • in a more and more innovative environment
  • in a tighter regulatory setting

Keyrus Biopharma benefits from the Research Tax Credit agreement (“Credit Impôt Recherche”)